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Abstract Mantle cell lymphoma (MCL) has a heteroge­
neous clinical course and is mainly an aggressive B cell 
non-Hodgkin lymphoma; however, there are some 
indolent cases The Ki-67 index, defined by the 
percentage of Ki-67-positive lymphoma cells on histo- 
pathological slides, has been shown to be a very 
powerful prognostic biomarker. The pathology panel of 
the European MCL Network evaluated methods to
assess the Ki-67 index including stringent counting, 
digital image analysis, and estimation by eyeballing. 
Counting of 2x500 lymphoma cells is the gold standard 
to assess the Ki-67 index since this value has been 
shown to predict survival in prospective randomized 
trials of the European MCL Network. Estimation by 
eyeballing and digital image analysis showed a poor 
concordance with the gold standard (concordance correla-
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tion coefficients [CCC] between 0.29 and 0.61 for 
eyeballing and CCC of 0.24 and 0.37 for two methods 
of digital image analysis, respectively). Counting a 
reduced number of lymphoma cells (2x 100 cells) showed 
high interobserver agreement (CCC=0.74). Pitfalls of the 
Ki-67 index are discussed and guidelines and recommen­
dations for assessing the Ki-67 index in MCL are given.
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Introduction
Mantle cell lymphoma (MCL) is a distinct B cell non- 
Hodgkin lymphoma with a poor clinical long-term 
outcome [1]. The currently used intensive treatment 
protocols including anti-CD20 antibody and autologous 
stem cell transplantation increased the response rate and 
remission duration but have failed to improve long-term 
overall survival so far [12]. The poor clinical outcome and 
the high number of relapses have stimulated research for 
alternative chemotherapeutic approaches for patients after 
a relapse and for high-risk patients as an alternative 
frontline therapy [12].
MCL is characterized by the translocation t(11;14) 
(q13;q32), which juxtaposes the immunoglobulin heavy- 
chain gene to the gene for cyclin D1 [8]. As a
consequence of the translocation, cases of MCL show 
constitutive upregulation of cyclin D1 expression. Since 
cyclin D1 promotes the transition from the G1 to S phase 
of the cell cycle, MCLs are characterized by cell cycle 
deregulation [8]. The cell proliferation rate, as measured 
by the Ki-67 index (the percentage of Ki-67-positive 
tumor cells), is correlated with the level of cyclin D1 
expression and other cell cycle regulators [16].
The Ki-67 index has been confirmed as a very 
powerful single prognostic factor for overall survival, 
with highly proliferative cases showing a much poorer 
outcome than tumors with low proliferation [21]. 
Recently, we demonstrated that the Ki-67 index retains 
its prognostic relevance in randomized prospective trials 
employing immunochemotherapy with the anti-CD20 
antibody rituximab [6]. Moreover, using the Ki-67 index 
in combination with clinical parameters such as age, 
performance status, lactate dehydrogenase, and leukocyte 
count (Mantle Cell Lymphoma International Prognostic 
Index), we were able to design a combined clinicobio- 
logical prognostic index for MCL [9]. Defining clinical 
risk scores might help to design patient-specific and 
lymphoma-specific therapy.
So far, in most of the published studies of other 
tumors, the stainings for Ki-67 were evaluated in a 
single center or by very few observers, thus avoiding 
the problem of interobserver variability. However, in 
order to allow the application of the Ki-67 index in 
clinical routine management of MCL with cut-off points
S. Cogliatti 
Institut für Pathologie,
St. Gallen, Switzerland
M. L. Hansmann
Department of Pathology, University of Frankfurt,
Frankfurt, Germany
P. M. Kluin
Department of Pathology and Laboratory Medicine, 
Groningen University Hospital,
Groningen, The Netherlands
R. Kodet
Department of Pathology and Molecular Medicine,
2nd Medical School and Faculty Hospital, Charles University, 
Prague, Czech Republic
Y. A. Krivolapov
Department of Immunohistochemistry,
Leningrad Regional Bureau of Pathology,
St. Petersburg, Russia
C. Loddenkemper • H. Stein 
Department of Pathology,
University Hospital Charité Campus Benjamin Franklin, 
Berlin, Germany
P. Moller • T. E. F. Barth
Department of Pathology, University of Ulm,
Ulm, Germany
K. Muller-Hermelink • A. Rosenwald 
Department of Pathology, University of Wurzburg, 
Wurzburg, Germany
G. Ott
Department of Clinical Pathology, 
Robert-Bosch-Krankenhaus,
Stuttgart, Germany
S. Pileri
Institute of Haematology and Clinical Oncology “L. and A. 
Seragnoli”, Unit of Haematopathology,
University of Bologna,
Bologna, Italy
E. Ralfkiaer
Rigshospitalet, University of Copenhagen,
Copenhagen, Denmark
G. Rymkiewicz 
Department of Pathology,
Maria Sklodowska-Curie Memorial Cancer Center,
Warsaw, Poland
<0 Springer
J Hematopathol (2009) 2:103-111 105
defining low-, intermediate-, or high-risk groups [5, 6] 
or incorporation of the Ki-67 index as a continuous 
variable in a prognostic index [9], it is of the highest 
importance to unify methods and establish guidelines for 
Ki-67 assessment. For this purpose, the pathology panel of 
the European MCL Network compared different methods 
of assessing the Ki-67 index on samples from patients 
with advanced-stage MCL treated within the randomized 
trials of European MCL Network and German Low Grade 
Lymphoma Study Group (GLSG). We provide recommen­
dations and guidelines for the future use of the Ki-67 
index in MCL.
Materials and methods
Lymphoma samples
Thirty-two primary diagnostic lymphnodebiopsy specimens 
from different patients with advanced-stage MCL treated 
within the clinical trials of the European MCL Network and 
GLSG[7, 13, 14] were randomly chosen. The stainings for 
Ki-67 were performed in different laboratories using 
diverse techniques and antibody clones, namely, Berlin 
(n = 10, Mib-1 antibody, alkaline phosphatase-antialkaline 
phosphatase method; Dako, Glostrup, Denmark), Kiel (n = 
7, Ki-S5 antibody, alkaline phosphatase-antialkaline 
phosphatase method, home-brewed reagents), Lübeck 
(n=2, Mib-1 antibody, Envision method; Dako, Glostrup, 
Denmark), and Würzburg (n =13, Mib-1 antibody, Envi­
sion method; Dako, Glostrup, Denmark). Only slides 
which showed unambiguous strong nuclear staining were 
analyzed. Therefore, three cases had to be excluded, 
resulting in 29 evaluable cases.
Ki-67 index
The Ki-67 index was defined as the percentage of Ki-67- 
positive tumor cells in representative areas (see below) of 
the lymphoma and was evaluated by counting, eyeballing, 
and digital image analysis.
Counting
Counting was performed by one observer (O.D.). To count 
the number of Ki-67-positive cells, two representative areas 
were chosen. A representative area was defined not to 
contain residual germinal centers, hot spots of proliferation 
or proliferating T cells. Hot spots of proliferation are areas 
of tumor cells (not germinal center residues) of less than 
two high-power fields in size (HPF, field of vision at x400 
magnification), which proliferate higher than the rest of the 
tumor. Usually, hot spots are already visible at a low-power
magnification. In each area, the positive cells among 500 
cells were counted using an eyepiece with a grid in a x400 
magnification. The Ki-67 index was calculated as the 
percentage of positive cells by averaging the values 
obtained for the two areas (count-Ki-67 index).
Recently, we demonstrated that the Ki-67 index assessed 
by counting 2 x 500 cells in representative areas is a reliable 
method to predict overall survival of MCL based on 
patients treated within prospective randomized trials of the 
European MCL Network [6]. Since this method has proven 
its clinical significance, the Ki-67 index obtained by 
counting (count-Ki-67 index) of 2 x 500 cells was consid­
ered the gold standard.
In order to reduce the number of counted cells in a 
second independent experiment, ten cases were randomly 
selected from the series. These cases were evaluated by four 
observers (OD, IO, WK, and HHW) without knowledge of 
the counted value. All observers counted the Ki-67-positive 
cells among 100 lymphoma cells in five consecutive HPF 
that had been selected as representative by each observer. 
The values for the first to the fifth count of 100 cells were 
registered separately.
Eyeballing
Eleven experienced expert hematopathologists evaluated all 
cases at an onsite pathology panel meeting. Each patholo­
gist estimated the Ki-67 index independently in represen­
tative areas of the lymphoma chosen by the pathologist 
himself and blinded for the results of the other investi­
gators.
Digital image analysis
Pictures of representative areas were obtained by the same 
observers who performed the counting. The images were 
analyzed blind (without knowledge of the results of 
counting) by an independent observer using a KS400 
system (Carl Zeiss, Jena, Germany). Automatic white 
balance was performed and, subsequently, RGB color 
thresholds were applied to identify positive and negative 
nuclei. Fixed threshold values were used. Two values were 
calculated: the percentage of positive nuclei and the 
percentage of the area covered by the positive nuclei.
Statistical methods
To quantify the degree of agreement between the quantita­
tive Ki-67 values generated by counting, eyeballing, and 
digital image analysis, concordance correlation coefficients 
(CCC) were estimated (Lin 1989; Barnhart 2002). A CCC 
of 1 indicates complete agreement, whereas a CCC of 0 
indicates no correlation. To obtain 95% confidence intervals,
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asymptotic confidence limits were estimated for comparisons 
of two methods and bootstrap confidence limits were 
estimated with 2,000 bootstrap samples for comparisons of 
more than two methods. The calculations used the SAS-macro 
CCC provided online by the Department of Biostatistics and 
Bioinformatics of the Duke University Medical Center, 
Durham, NC, USA. Quantitative values were described with 
median and range, and group comparisons for paired samples 
were performed using the nonparametric signed rank test. 
Single extreme values not representative for the range of 
values were excluded. The working significance level was 
5%. All analyses were performed using SAS Version 9.1 (SAS 
Institute, Cary, NC, USA).
Results
Gold standard
The Ki-67 index assessed by counting 2 x 500 cells showed 
a median of 14.7% (minimum 2.1%, maximum 91%) in the 
analyzed series. Two cases of highly proliferative lympho­
mas (Ki-67 index >80% by counting; see Fig. 1) had to be 
excluded from further analysis in order to avoid the 
detection of pseudocorrelations, resulting in a median of 
14.6% and a maximum of 50.9%.
Estimation by eyeballing
The Ki-67 index estimated by eyeballing by 11 
experienced hematopathologists deviated considerably 
between individual observers (deviation up to 85%) 
and from the count-Ki-67 index (deviation up to 72%; 
Fig. 1). The concordance to the value obtained by 
eyeballing compared to counting was poor (CCC between 
0.29 and 0.61) and did not improve after averaging all 
values for the 11 pathologists (CCC=0.53; Table 1). The 
concordance between all 11 individual pathologists was 
also poor (CCC=0.56).
Fig. 1 Variability of Ki-67 eyeballing. Plot of Ki-67 values estimated 
by eyeballing by 11 experienced hematopathologists vs. Ki-67 values 
obtained via counting of 2*500 cells (gold standard). Each patholo­
gist is represented by one color. In order to visualize identical 
estimation values corresponding to the same counting values, counting 
values are minimally scattered around the true values
Digital image analysis
Ki-67 values obtained by digital image analysis deviated 
largely from the values obtained by counting. Values as 
percentage of nuclei were 4.8% higher than the count-Ki- 
67 index (median, p =0.034, signed rank test) and values as 
percentage of area were 8.5% lower than the count-Ki-67 
index (median, p =0.0011, signed rank test). The concor­
dance of digital image analysis with the count-Ki-67 index 
was poor for both methods of analysis used (CCC 0.24 for 
percentage of nuclei and 0.37 for percentage of positive 
area; Table 2). All values as percentage of nuclei were 
higher than the percentage of area values (p<0.0001,
Table 1 Values for the 11 pathologists
Measure P1 vs. 
count
P2 vs. 
count
P3 vs. 
count
P4 vs. 
count
P5 vs. 
count
P6 vs. 
count
P7 vs. 
count
P8 vs. 
count
P9 vs. 
count
P10
vs.
count
P11
vs.
count
Mean
vs.
count
All
pathologists
N 27 27 27 27 27 26 25 24 24 27 27 27 22
CCC 0.61 0.38 0.38 0.61 0.55 0.49 0.46 0.31 0.54 0.51 0.29 0.53 0.56
95%
LCL
0.33 0.15 0.07 0.33 0.30 0.22 0.10 0.05 0.20 0.25 0.07 0.25 0.36
95%
UCL
0.79 0.58 0.62 0.79 0.73 0.68 0.71 0.54 0.77 0.70 0.49 0.73 0.68
P l—P ll  pathologists 1-11, mean the mean of all pathologists, CCC concordance correlation coefficients, LCL lower confidence limit, UCL upper 
confidence limit
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Table 2 Values of percentage of 
nuclei and percentage of area
CCC concordance correlation 
coefficients
Measure % nuclei vs. count % area vs. count % nuclei vs. % area
N 27 27 27
CCC 0.24 0.37 0.46
95% LCL 0.00 0.04 0.25
95% UCL 0.47 0.62 0.63
signed rank test) and concordance between percentage of 
nuclei and percentage of area was low (CCC=0.46).
Counting 100 cells per representative area
In order to evaluate the effect of reducing the number 
of counted cells on the interobserver concordance, 100 
cells were counted in five consecutive HPF by four 
observers in ten cases. Again, to avoid the detection of 
pseudocorrelations, two cases with high Ki-67 values 
had to be excluded from analysis. As expected, the 
intraobserver concordance (CCC=0.83-0.96) was higher 
than the interobserver concordance (CCC=0.68) if 100 
cells in one HPF were counted. The concordance 
between the observers increased with each additional 
100 cells analyzed, with the strongest increase in 
concordance between the first and the second HPF with 
1x100 cells in each (CCC=0.68 and 0.74, respectively; 
Table 3, Fig. 2) and only minor improvement with further 
increase or the number of cells to be counted. The 
concordance with the gold standard of 2x500 counted 
cells increased in average with each step of additional 100 
cells counted. The average CCC for 2x100 compared to 
the gold standard was 0.79. By counting more than 2 x 100 
cells, a further relevant increase of the CCC with the gold 
standard could be achieved in only two of four observers 
(data not shown).
Discussion
Which specimens should be assessed for Ki-67?
Several studies have demonstrated the prognostic signifi­
cance of the Ki-67 index in MCL [6, 9, 11, 17- 19, 21]. All 
of these above-mentioned studies, including our own of the 
European MCL Network, evaluated the Ki-67 index in the 
primary biopsy specimens. To the best of our knowledge, 
no studies analyzing the prognostic role of the Ki-67 index 
in relapsed disease have been published so far. Thus, to 
date, the use of the Ki-67 index as a prognostic marker has 
only been proven in specimens obtained at primary 
diagnosis. Of note, if tissues are fixed with Bouin’s 
solution, an immunohistochemistry for Ki-67 is not 
possible. Therefore, a fixation in buffered formalin solution 
is mandatory.
In our study, we used lymph node specimens to evaluate 
different methods of calculating the Ki-67 index. However, 
other studies have also included extranodal biopsy speci­
mens. We generally recommend analysis of nodal and 
extranodal specimens but not bone marrow (see below) to 
evaluate the Ki-67 index. In any specimen, but especially in 
extranodal specimens, only samples with dense lymphoma 
areas should be analyzed because the Ki-67 index is based 
on the percentage of Ki-67-positive lymphoma cells, 
ignoring reactive background cells. Thus, minimally infil-
Fig. 2 Interobserver agreement 1 00
for Ki-67 assessment by count­
ing 1*100 to 5*100 cells and
using the average. The concor- 0 gg
dance correlation coefficient 
(CCC) was estimated with four 
raters on eight samples
0.60
Ô  Springer
108 J Hematopathol (2009) 2:103-111
Table 3 Counting 100 cells per representative area
N CCC 95% CI
First 100 cells 8 0.68 0.54-0.79
First + second 100 cells (mean) 8 0.74 0.63-0.84
First-third 100 cells (mean) 8 0.76 0.63-0.84
First-fourth 100 cells (mean) 8 0.78 0.62-0.87
First-fifth 100 cells (mean) 8 0.80 0.68-0.88
CCC concordance correlation coefficients, Cl confidence interval
trated biopsy specimens or specimens with a prominent 
reactive background should be excluded. The sample 
size should allow a minimum of five independent HPF 
(at x400 magnification) to be selected for the counting. 
Thus, a considerable percentage of punch needle biopsy 
specimens is too small, especially since the selection of 
a representative area is not possible in some cases (see 
below).
All above-mentioned studies evaluated the Ki-67 
index on histopathology slides. However, flow cytom­
etry is increasingly being used for nuclear antigens in 
the diagnosis of lymphomas from blood and bone 
marrow aspirates and lymph node fine needle aspirates 
[2, 3]. The advantage of flow cytometry is the reliable 
standardization of the method and the possibility to restrict 
the measurement of proliferative index to the tumor cells
Fig. 3 Areas of proliferating T 
cells in the case of a classical 
MCL. The MCL cells are char­
acterized by CD20 expression 
and infiltrating T cells by stain­
ing for CD3. The Ki-67 index is 
higher in the T cell-rich area 
(corresponding areas are marked 
by an arrow). Double staining 
for CD20/Ki-67 of the T cell- 
rich area at a higher magnifica­
tion shows numerous Ki-67 
positive T cells (red) which are 
negative for the B cell marker 
CD20 (brown)
excluding reactive T cells from the analysis. Since the 
majority of MCLs are leukemic [2], flow cytometry on 
peripheral blood might represent an easily assessable 
source for the Ki-67 analysis. However, in chronic 
lymphocytic leukemia, Ki-67 values of peripheral blood 
and lymph node compartment differs significantly as the 
proliferative compartment probably resides predominantly 
in solid tissues [15]. Therefore, future studies have to 
evaluate whether Ki-67 staining of peripheral blood 
cells and bone marrow are appropriate and representa­
tive for the proliferation in solid tissue and whether 
flow cytometry of blood, bone marrow, or lymph node 
biopsies may substitute for the Ki-67 index obtained by 
histology on tissue sections. To date, the use of flow 
cytometry of blood, bone marrow, and lymph nodes 
cannot be regarded as a standard approach to assess the 
Ki-67 index in MCL.
How should the Ki-67 index be assessed in MCL?
The Ki-67 index varies between different MCL subtypes 
defined by cytology, with blastic and pleomorphic MCL 
showing the highest proliferation on average [21]. 
However, there is great variability in the Ki-67 index 
within the subgroup of classical MCL, with values 
reaching up to the range found in blastic or pleomorphic 
MCL [21]. Thus, the blastic or pleomorphic subtype of 
MCL should only be diagnosed on the basis of cytology,
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Fig. 4 Pitfalls in the selection 
of representative areas for the 
Ki-67 index in MCL. The upper 
panel shows two examples of 
Ki-67 staining. In the middle 
panel, residual germinal centers 
are marked by an arrow, hot 
spots of proliferation by an 
asterisk, and proliferating T cells 
by an arrowhead. In the lower 
panel, suggested representative 
areas for assessing the Ki-67 
index are indicated by circles
not of the Ki-67 index. On the other hand, in some cases 
of classical MCL, a high proliferation rate may also be 
expected.
Digital image analysis is increasingly being used to 
analyze immunohistochemical stainings in lymphoma 
research and has been successfully applied to assess 
the Ki-67 index in several solid tumors and lymphomas 
[4, 20, 22]. However, we did not find a convincing 
concordance of the digital image analysis with our gold 
standard, the count-Ki-67 index. MCL are composed of 
relatively small cells with a narrow rim of cytoplasm [1, 
10, 21]. Since the lymphoma cells are usually densely 
packed, currently available software for digital image 
analysis often fails to recognize single nuclei. Never­
theless, we believe that future development may prove 
digital image analysis to be a valuable tool for the 
quantification of immunohistochemistry. Moreover, it is 
theoretically possible that the Ki-67 values obtained by
digital image analysis might correlate with the clinical 
outcome despite the poor correlation with the counted 
value. Therefore, image analysis on a larger set of 
lymphomas and a clinical correlation will be necessary 
to finally solve this question.
As shown above, eyeballing and digital image 
analysis (with the method used in this study) did not 
show an acceptable concordance with the count-Ki-67 
index and the interobserver correlation was poor. We 
cannot rule out completely that estimation of the Ki-67 
index by eyeballing might still be of relevance in the 
future, since guidelines as reported herein and tools like 
software for training of estimation (Y. Krivolapov, 
personal communication) might improve the estimation 
skills of pathologists. Whether the staining method/color 
or the selection of the biopsy specimen influenced the 
estimation performance of the pathologist has to be 
determined in future studies. Although previous analysis
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showed that the mitotic count did not reach the 
predictive value of the Ki-67 index (data not shown), 
future studies comparing these two methods are also 
needed. To date, our results confirmed that quantitative 
count of lymphoma cells at a high magnification 
represents the method of choice to obtain the Ki-67 
index and yields the best intraobserver and interobserver 
reproducibility.
Counting 2 x 500 cells is very time-consuming and will 
probably not be applicable in clinical routine. Thus, 
various methods for the determination of the Ki-67 
index were evaluated and compared to define the 
optimal approach which provides reliable and reproduc­
ible results and can be used in multiobserver studies 
with a minimum of workload. Accordingly, we evaluat­
ed the effect of reducing the number of counted cells on 
the interobserver concordance. Increasing the number of 
counted cells improved both interobserver and intra­
observer concordance, with the strongest increase in 
concordance between 1x100 counted cells and 2x100 
counted cells. The values obtained by counting 2x100 
cells show a high concordance with the gold standard. 
We thus recommend assessing the Ki-67 index in MCL 
by counting the percentage of positive cells among 200 
lymphoma cells in two independent, representative 
lymphoma areas at a high magnification (HPF). This 
method allows a reliable assessment of the Ki-67 index 
in <2 min per case. The Ki-67 index in MCL can be 
used as a continuous parameter or with cut-off values to 
define risk groups [6, 9]. However, in any case, a reliable 
Ki-67 value provided by the pathologist will be necessary.
Since Ki-67-positive cells are not homogenously distrib­
uted, the selection of representative lymphoma areas for the 
counting of the Ki-67 index is of crucial importance. 
Several areas of high proliferation should be excluded: (1) 
“hot spots” of proliferation (see the “Materials and 
methods” section for the definition), (2) T cells in the 
periphery of lymphoma nodules (Fig. 3), and (3) residual 
germinal centers. The pitfalls in the selection of represen­
tative areas in MCL are outlined in Fig. 4. “Hot spots” of 
proliferation are not suitable to assess a prognostic Ki-67 
value in MCL [21]. However, even if our guidelines are 
followed, the selection of the representative area might still 
have a subjective element.
We have to stress that the prognostic relevance of the Ki- 
67 index in MCL so far has been proven only in 
retrospective analysis. To date, the Ki-67 index has never 
been applied as a stratifying marker for clinical decision 
making. Therefore, the use of the Ki-67 index as a 
prospectively evaluated factor for treatment stratification 
has to be analyzed prospectively before a general use of this 
marker outside of studies can be recommended. Neverthe­
less, the recommendations and guidelines presented in this
study will be of great importance for the design of such 
future trials.
In summary, we recommend assessing the Ki-67 index 
as a prognostic tool in MCL specimens:
• obtained at primary diagnosis before any treatment.
• from nodal sites but not from bone marrow. The 
eligibility of biopsies from extranodal sites has to be 
analyzed in future studies.
• of a minimum size that allows at least five independent 
representative HPF to be selected.
• in 200 lymphoma cells, by counting the positive cells 
among 100 lymphoma cells in two HPF each.
• in representative areas which do not include residual 
germinal centers, hot spots of proliferation, or prolifer­
ating T cells.
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